The Avigilon Patent License Program

The Avigilon Patent License Program

"The Early Adopter Plan further enhances the value of joining the License Program," said Chris Capuano, Avigilon's Vice President of Licensing. "The License Program makes fundamental patents available to industry participants, providing them with greater freedom to operate. We encourage all interested companies to join the License Program by taking advantage of the Early Adopter Plan.

Login to read this IPVM discussion.
Why do I need to log in?
IPVM conducts unique testing and research funded by member's payments enabling us to offer the most independent, accurate and in-depth information.

****** ******** *****'* ******* *******

...** ******** ** **** ********* ***** ******** ********* * **-*** window ** ***** **** * ******, *********-**** ****** ********* ********* with **.

** *** ********** ** ****** **** **** ***** ***** **** something **** **** *******. *** ***** ***** ** ****** ** the **** ** ******* *********.

*** ***** ***** ** ****** ** *** **** ** ******* Licensees.

*** ***** ***** ** ****** ** *** **** ** ****** Litigants. ;)

***, ** ***** ** **** **** ********* ** **** **** so.

**** **** *** **** ***************:

****** *** *** *********. ** *'** ***** ** *** ****** today $** *******, ******* ** **** $** ******* ** * relative ***** *********. ** ******* **** ** *** ****** ******** and ** *** **** *** ***** **** * ******** ** –if *** *** ******** ************ **'** **** **** **** ** analytics.

** ****** ******* *.*% ** *% ***, ** *** *** basically **** ********* **** *** ****** ******* *** ** ****** discount ******* *** ****, **** ******** ************ *** ** ***** obscure ************* ** **** **** ***** ****** ***** ***** ** doesn't ****** **** ***** ** ****** **** **** ** **** simply ** **** *** *****.

** *** ****, ** ******’* – * ***'* ***** ** would ** * ********* ********** ** *** **** ***** ****** industry ************ **** ****** * ****** ********. *** ** ********* plan ** ****** **** *** ******** ** ****. *** ** I'll ***** ** ** ** *** ** **** ** ********** on **** *** ***** *** ********** ** *** ***** ****** that ** *** ** **** ** ******. *** *** **** the ******* *****.

*** **** *** ***** ***** ** ****** **** **** ********** or **** ** ****** ********** **** *** ********, ** *** put ** ** ***** ** * ******* **** ** ***** we *** **** ** *********. *** ** ** - **’* simply **** *** ********* ** ** ***** *** *******, ***'* say *** ** ****.

*** ** ** ***** **** **** **** ******* ****-**** ******. And ** ** **** ** *****. ** ** ** *******, as * ***** ** ********* ** *** **** ******* ****** up ***** *** ********* *** ** **** **** ***** ****** will **********, ***** ********* *** *** ********* *** **** ******* in **** **** ** **** ***** ** ******** **** *** required.

*** ** ** **** ******* ** *** ***** ** ******** they ***** *** **** *** ******. *** ** ***** ** a - **** ****** *********** * **** ** * *********** increase ** ******* ** * ****** ******** ** ******* ********. And ** * *****, **** ******* **** ** ******** ** that, ** ****** ******** *** ********* *******, ****** ******* **** year, **** * *** ****** ***.

*** ** *****, ****, **** ***** ****. * ****** ** other *****, ** ****** ***'* ****** - *** ****, **'** getting ********** ******** ** *** ********. *** ** ****** ****** the ********* ******* ** ***** ****** – ** ****** *** needle ** *** **** **** ** ****, *** *******.

** ** *** ** ** * * ** * ** 4 ***** ** ****** **** *** ******** *** ** *, and * * ***** ** **** ** ** **** ****** and ***** ** **** ** * ****** **** ***********, *** highly **********.